[
  {
    "title": "艾迪药业：瞄准“抗艾”药物大市场 国内首个三联单片复方制剂复邦德获批上市",
    "href": "http://stock.jrj.com.cn/2023/01/05171637261814.shtml",
    "datetime": "2023-01-05 17:16:19",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：ACC008片获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2023/01/05163337261423.shtml",
    "datetime": "2023-01-05 16:33:33",
    "code": "688488"
  },
  {
    "title": "艾迪药业重磅国产抗艾药复邦德获批上市 国内抗HIV病毒治疗市场或迎格局转变",
    "href": "http://stock.jrj.com.cn/2023/01/04164337258632.shtml",
    "datetime": "2023-01-04 16:43:43",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：抗艾滋病领域1类创新药ACC008片获批上市",
    "href": "http://stock.jrj.com.cn/2023/01/04162937258517.shtml",
    "datetime": "2023-01-04 16:29:08",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：拟以债转股的方式对3家子公司合计增资1.675亿元",
    "href": "http://stock.jrj.com.cn/2022/12/30202737250972.shtml",
    "datetime": "2022-12-30 20:27:27",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：董事长傅和亮完成增持137.478万股",
    "href": "http://stock.jrj.com.cn/2022/11/04180537113468.shtml",
    "datetime": "2022-11-04 18:05:55",
    "code": "688488"
  },
  {
    "title": "艾迪药业：核心产品商业化进展顺利 艾邦德第三季度销售收入环比增七成",
    "href": "http://stock.jrj.com.cn/2022/10/29174437105078.shtml",
    "datetime": "2022-10-29 17:44:18",
    "code": "688488"
  },
  {
    "title": "艾迪药业：核心产品商业化进展顺利 艾邦德第三季度销售收入环比增七成",
    "href": "http://stock.jrj.com.cn/2022/10/29174437096759.shtml",
    "datetime": "2022-10-29 17:44:18",
    "code": "688488"
  },
  {
    "title": "相关产品是否存在市场竞争力下降等，艾迪药业回复问询函",
    "href": "http://stock.jrj.com.cn/2022/09/30100137033085.shtml",
    "datetime": "2022-09-30 10:01:04",
    "code": "688488"
  },
  {
    "title": "募投项目中止、募资理财 艾迪药业对外收购难提升业绩",
    "href": "http://stock.jrj.com.cn/2022/09/16084136999410.shtml",
    "datetime": "2022-09-16 08:41:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业撤回注射用乌司他丁仿制药项目上市申请",
    "href": "http://stock.jrj.com.cn/2022/09/15103636996367.shtml",
    "datetime": "2022-09-15 10:36:16",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488)：增加2022年度日常关联交易额度预计",
    "href": "http://stock.jrj.com.cn/2022/09/15090336996044.shtml",
    "datetime": "2022-09-15 09:03:41",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：拟使用超募资金530万元永久补充流动资金",
    "href": "http://stock.jrj.com.cn/2022/09/14210636995375.shtml",
    "datetime": "2022-09-14 21:06:23",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：撤回注射用乌司他丁仿制药项目上市申请",
    "href": "http://stock.jrj.com.cn/2022/09/14210436995376.shtml",
    "datetime": "2022-09-14 21:04:57",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：拟使用不超3.8亿元暂时闲置募资进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/09/14210336995378.shtml",
    "datetime": "2022-09-14 21:03:46",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：撤回乌司他丁注射液仿制药项目注册临床试验申请",
    "href": "http://stock.jrj.com.cn/2022/09/02180036968931.shtml",
    "datetime": "2022-09-02 18:00:31",
    "code": "688488"
  },
  {
    "title": "止盈转亏 艾迪药业2022年半年度净亏损6819.16万元",
    "href": "http://stock.jrj.com.cn/2022/08/26092636939145.shtml",
    "datetime": "2022-08-26 09:26:39",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：拟与北京安普设艾普医学、聚焦于HIV领域及其他潜在可获益领域的医学检验服务",
    "href": "http://stock.jrj.com.cn/2022/08/22181436922348.shtml",
    "datetime": "2022-08-22 18:14:59",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：与药石科技拟在抗新冠肺炎病毒3CL蛋白酶抑制剂创新靶点和创新化合物领域共同开发新药",
    "href": "http://stock.jrj.com.cn/2022/08/22181236922353.shtml",
    "datetime": "2022-08-22 18:12:16",
    "code": "688488"
  },
  {
    "title": "南大药业是否存在重大偿债风险？艾迪药业回复问询函",
    "href": "http://stock.jrj.com.cn/2022/07/26130836843210.shtml",
    "datetime": "2022-07-26 13:08:56",
    "code": "688488"
  },
  {
    "title": "分析南大药业的核心竞争力？艾迪药业收上交所问询函",
    "href": "http://stock.jrj.com.cn/2022/07/20133936828181.shtml",
    "datetime": "2022-07-20 13:39:23",
    "code": "688488"
  },
  {
    "title": "艾迪药业大客户订单减半致再亏2230万 溢价7.8倍投资同行公司对冲业务风险",
    "href": "http://stock.jrj.com.cn/2022/07/20121136828044.shtml",
    "datetime": "2022-07-20 12:11:35",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488)：对外投资,投资金额为人民币8600万元",
    "href": "http://stock.jrj.com.cn/2022/07/19094036824158.shtml",
    "datetime": "2022-07-19 09:40:44",
    "code": "688488"
  },
  {
    "title": "艾迪药业拟以8600万的价格受让盛丰医疗持有的南大药业19.96%的股权",
    "href": "http://stock.jrj.com.cn/2022/07/18213136822660.shtml",
    "datetime": "2022-07-18 21:31:52",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：拟以8600万元受让南大药业19.96%股权",
    "href": "http://stock.jrj.com.cn/2022/07/18171936821644.shtml",
    "datetime": "2022-07-18 17:19:41",
    "code": "688488"
  },
  {
    "title": "艾迪药业：拟8600万元受让盛丰医疗持有的南大药业19.96%的股权",
    "href": "http://stock.jrj.com.cn/2022/07/18171836821642.shtml",
    "datetime": "2022-07-18 17:18:47",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：285.92万股限售股将于7月20日解禁上市",
    "href": "http://stock.jrj.com.cn/2022/07/12171336803807.shtml",
    "datetime": "2022-07-12 17:13:43",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：并购成长及其一致行动人的合计持股比例降至4.99998%",
    "href": "http://stock.jrj.com.cn/2022/07/08215636796016.shtml",
    "datetime": "2022-07-08 21:56:27",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)及子公司1月以来累积获得政府补助2948.04万元",
    "href": "http://stock.jrj.com.cn/2022/07/08203536795762.shtml",
    "datetime": "2022-07-08 20:35:46",
    "code": "688488"
  },
  {
    "title": "艾迪药业股东乐扬凯睿减持270.7万股 套现3670.13万 2021年公司亏损2998.56万",
    "href": "http://stock.jrj.com.cn/2022/06/21205236747643.shtml",
    "datetime": "2022-06-21 20:52:48",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：乐扬凯睿以集中竞价共减持270.6954万股",
    "href": "http://stock.jrj.com.cn/2022/06/21174636746895.shtml",
    "datetime": "2022-06-21 17:46:18",
    "code": "688488"
  },
  {
    "title": "艾迪药业：安赛莱单方面向珀金埃尔默发出解除授权合同通知",
    "href": "http://stock.jrj.com.cn/2022/06/07113236708412.shtml",
    "datetime": "2022-06-07 11:32:53",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：子公司单方面解除珀金埃尔默HIV诊断试剂及仪器中国区总代理权",
    "href": "http://stock.jrj.com.cn/2022/06/06212536707159.shtml",
    "datetime": "2022-06-06 21:25:06",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488)：实际控制人增持股份进展",
    "href": "http://stock.jrj.com.cn/2022/05/27084336683300.shtml",
    "datetime": "2022-05-27 08:43:47",
    "code": "688488"
  },
  {
    "title": "钢铁类上市公司大多存在破净问题？网友喊话艾迪药业：股吧有不法分子摸黑公司！请公司回应一下，以正视听",
    "href": "http://stock.jrj.com.cn/2022/05/26210436682563.shtml",
    "datetime": "2022-05-26 21:04:19",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：董事长傅和亮已累计增持59.174万股",
    "href": "http://stock.jrj.com.cn/2022/05/26203036682451.shtml",
    "datetime": "2022-05-26 20:30:49",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：第一期员工持股计划完成非交易过户并出售完毕",
    "href": "http://stock.jrj.com.cn/2022/05/11190036635546.shtml",
    "datetime": "2022-05-11 19:00:04",
    "code": "688488"
  },
  {
    "title": "主营业务及核心竞争力是否发生较大变化？艾迪药业答年报问询函",
    "href": "http://stock.jrj.com.cn/2022/05/11120536632114.shtml",
    "datetime": "2022-05-11 12:05:11",
    "code": "688488"
  },
  {
    "title": "艾迪药业2022年第一季度亏损2230.27万 管理费用及研发费用增加",
    "href": "http://stock.jrj.com.cn/2022/05/03185036546067.shtml",
    "datetime": "2022-05-03 18:50:44",
    "code": "688488"
  },
  {
    "title": "艾迪药业2021年亏损2998.56万同比由盈转亏 董事长傅和亮薪酬70.91万",
    "href": "http://stock.jrj.com.cn/2022/04/15143136343454.shtml",
    "datetime": "2022-04-15 14:31:45",
    "code": "688488"
  },
  {
    "title": "艾迪药业：创新药持续发力 聚焦HIV领域深度布局",
    "href": "http://stock.jrj.com.cn/2022/04/14220436338925.shtml",
    "datetime": "2022-04-14 22:04:33",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：2021年度净亏损2998.56万元",
    "href": "http://stock.jrj.com.cn/2022/04/14204636337711.shtml",
    "datetime": "2022-04-14 20:46:27",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：董事长兼总裁傅和亮拟增持1000万-1500万元的股份",
    "href": "http://stock.jrj.com.cn/2022/04/08183336273458.shtml",
    "datetime": "2022-04-08 18:33:26",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：减持期过半 乐扬凯睿累计减持193.26万股",
    "href": "http://stock.jrj.com.cn/2022/03/22173434861249.shtml",
    "datetime": "2022-03-22 17:34:17",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：向73名激励对象授予563万股限制性股票",
    "href": "http://stock.jrj.com.cn/2022/03/11222634816001.shtml",
    "datetime": "2022-03-11 22:26:35",
    "code": "688488"
  },
  {
    "title": "艾迪药业选举傅和亮担任公司董事长 2021年公司亏损3229.89万",
    "href": "http://stock.jrj.com.cn/2022/03/11200734815469.shtml",
    "datetime": "2022-03-11 20:07:03",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：公司核心技术人员离职",
    "href": "http://stock.jrj.com.cn/2022/03/11180734814856.shtml",
    "datetime": "2022-03-11 18:07:38",
    "code": "688488"
  },
  {
    "title": "艾迪药业2021年亏损3229.89万同比由盈转亏 高毛利率产品销售同比减少",
    "href": "http://stock.jrj.com.cn/2022/02/25223034468603.shtml",
    "datetime": "2022-02-25 22:30:30",
    "code": "688488"
  },
  {
    "title": "艾迪药业3名股东减持914.71万股 套现1.54亿 2021年公司亏损2200万-3300万",
    "href": "http://stock.jrj.com.cn/2022/02/07201034303015.shtml",
    "datetime": "2022-02-07 20:10:49",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：并购成长、高投鑫海及人才基金完成减持2.18%股份",
    "href": "http://stock.jrj.com.cn/2022/02/07173134302201.shtml",
    "datetime": "2022-02-07 17:31:48",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：2021年度预亏2200万元-3300万元",
    "href": "http://stock.jrj.com.cn/2022/01/28211234248747.shtml",
    "datetime": "2022-01-28 21:12:31",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：与中艾协就中国艾滋病防控事业达成初步合作意向",
    "href": "http://stock.jrj.com.cn/2022/01/24180434205397.shtml",
    "datetime": "2022-01-24 18:04:18",
    "code": "688488"
  },
  {
    "title": "艾迪药业聘任张静、Hong Qi均为高级副总裁 2021年第三季度公司亏损622.04万",
    "href": "http://stock.jrj.com.cn/2022/01/19213034175630.shtml",
    "datetime": "2022-01-19 21:30:03",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：拟推2022年限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2022/01/19192034175217.shtml",
    "datetime": "2022-01-19 19:20:46",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：乐扬凯睿已减持0.62681%的股份 持股降至4.99999%",
    "href": "http://stock.jrj.com.cn/2022/01/11211434147682.shtml",
    "datetime": "2022-01-11 21:14:28",
    "code": "688488"
  },
  {
    "title": "艾迪药业：募投项目变更后专注优势赛道 聚焦HIV领域",
    "href": "http://stock.jrj.com.cn/2022/01/05175834124941.shtml",
    "datetime": "2022-01-05 17:58:56",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：就共同开发抗HIV长效治疗药物项目与南京药石科技签订项目合作开发框架合同",
    "href": "http://stock.jrj.com.cn/2021/12/28204734077898.shtml",
    "datetime": "2021-12-28 20:47:24",
    "code": "688488"
  },
  {
    "title": "艾迪药业IPO六个药品募投项目四个变更：上交所要求说明短期调整战略方向原因",
    "href": "http://stock.jrj.com.cn/2021/12/27111134069313.shtml",
    "datetime": "2021-12-27 11:11:44",
    "code": "688488"
  },
  {
    "title": "艾迪药业签订《技术转让合同》 技术转让费1亿（含税）",
    "href": "http://stock.jrj.com.cn/2021/12/24195034059304.shtml",
    "datetime": "2021-12-24 19:50:53",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：拟将抗肿瘤在研新药ACC006项目的技术秘密等相关权益转让给力鑫生物",
    "href": "http://stock.jrj.com.cn/2021/12/24170734058265.shtml",
    "datetime": "2021-12-24 17:07:52",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：核心技术人员李文全、胡雄林辞职",
    "href": "http://stock.jrj.com.cn/2021/12/24165934058188.shtml",
    "datetime": "2021-12-24 16:59:41",
    "code": "688488"
  },
  {
    "title": "艾迪药业与珀金埃尔默达成战略合作 携手开拓艾滋病诊疗领域新合作",
    "href": "http://stock.jrj.com.cn/2021/12/20195134036572.shtml",
    "datetime": "2021-12-20 19:51:01",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：全资子公司获得获得珀金埃尔默HIV检测试剂及仪器在中国大陆的总代理权",
    "href": "http://stock.jrj.com.cn/2021/12/20180134035331.shtml",
    "datetime": "2021-12-20 18:01:04",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：艾诺韦林片获得药品补充申请批准通知书",
    "href": "http://stock.jrj.com.cn/2021/12/16182534025148.shtml",
    "datetime": "2021-12-16 18:25:35",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：与中国医保签订战略合作协议",
    "href": "http://stock.jrj.com.cn/2021/12/09172533990530.shtml",
    "datetime": "2021-12-09 17:25:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业：艾邦德成功进入2021年国家医保目录",
    "href": "http://stock.jrj.com.cn/2021/12/03172733960785.shtml",
    "datetime": "2021-12-03 17:27:18",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：抗艾滋病领域国家1类新药艾诺韦林片首次被纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2021/12/03171233960584.shtml",
    "datetime": "2021-12-03 17:12:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：乐扬凯睿拟减持不超1%股份",
    "href": "http://stock.jrj.com.cn/2021/11/30175033944948.shtml",
    "datetime": "2021-11-30 17:50:03",
    "code": "688488"
  },
  {
    "title": "艾迪药业大股东减持2500万股 业绩大降 研发投入却大增",
    "href": "http://stock.jrj.com.cn/2021/11/10075933830720.shtml",
    "datetime": "2021-11-10 07:59:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：减持期过半 5%以上股东已减持1%股份",
    "href": "http://stock.jrj.com.cn/2021/11/09171933828101.shtml",
    "datetime": "2021-11-09 17:19:33",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：第三季度净亏损622.04万元",
    "href": "http://stock.jrj.com.cn/2021/10/27220433764650.shtml",
    "datetime": "2021-10-27 22:04:57",
    "code": "688488"
  },
  {
    "title": "艾迪药业前三季度营收稳步增长 艾邦德获权威认可未来可期",
    "href": "http://stock.jrj.com.cn/2021/10/27182933763301.shtml",
    "datetime": "2021-10-27 18:29:59",
    "code": "688488"
  },
  {
    "title": "艾迪药业2021年半年度净利1286.1万元 同比净利减少47.49%",
    "href": "http://stock.jrj.com.cn/2021/08/26201533326568.shtml",
    "datetime": "2021-08-26 20:15:27",
    "code": "688488"
  },
  {
    "title": "艾迪药业上半年营收稳步增长 抗HIV创新药获重大突破",
    "href": "http://stock.jrj.com.cn/2021/08/26195233326795.shtml",
    "datetime": "2021-08-26 19:52:18",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)半年度净利润1286.1万元 同比下降47.49%",
    "href": "http://stock.jrj.com.cn/2021/08/26193933326151.shtml",
    "datetime": "2021-08-26 19:39:51",
    "code": "688488"
  },
  {
    "title": "艾迪药业股东拟询价转让，初步确定价格为17.26元/股",
    "href": "http://stock.jrj.com.cn/2021/08/03093533193599.shtml",
    "datetime": "2021-08-03 09:35:20",
    "code": "688488"
  },
  {
    "title": "艾迪药业：股东拟询价转让420万 转让价格17.13元/股",
    "href": "http://stock.jrj.com.cn/2021/07/29102633168428.shtml",
    "datetime": "2021-07-29 10:26:41",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：Starr International拟询价转让1%的股份",
    "href": "http://stock.jrj.com.cn/2021/07/28180233164792.shtml",
    "datetime": "2021-07-28 18:02:45",
    "code": "688488"
  },
  {
    "title": "艾迪药业积极打造原料制剂一体化格局 人源蛋白业务延展前景值得期待",
    "href": "http://stock.jrj.com.cn/2021/07/25152533144978.shtml",
    "datetime": "2021-07-25 15:25:41",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：股东并购成长、高投鑫海、人才基金计划拟减持不超6%股份",
    "href": "http://stock.jrj.com.cn/2021/07/20163533124589.shtml",
    "datetime": "2021-07-20 16:35:47",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：乌司他丁新适应症I期临床试验首例受试者成功入组",
    "href": "http://stock.jrj.com.cn/2021/07/18155933112415.shtml",
    "datetime": "2021-07-18 15:59:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业：国产1类新药艾邦德获批 创新药布局进入快车道",
    "href": "http://stock.jrj.com.cn/2021/06/29095033014779.shtml",
    "datetime": "2021-06-29 09:50:15",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：艾诺韦林片获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/28174833010883.shtml",
    "datetime": "2021-06-28 17:48:56",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：抗艾滋病领域1类新药ACC007药品批准证明文件待领取",
    "href": "http://stock.jrj.com.cn/2021/06/27160633002680.shtml",
    "datetime": "2021-06-27 16:06:03",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：2020年度权益分派10派0.48元 股权登记日6月23日",
    "href": "http://stock.jrj.com.cn/2021/06/17161832947895.shtml",
    "datetime": "2021-06-17 16:18:59",
    "code": "688488"
  },
  {
    "title": "艾迪药业：南京方生和医药科技有限公司（“方生和”）为甲磺酸仑伐替尼胶囊仿制药产品的持有人",
    "href": "http://stock.jrj.com.cn/2021/05/27173432830688.shtml",
    "datetime": "2021-05-27 17:34:33",
    "code": "688488"
  },
  {
    "title": "A股异动丨艾迪药业(688488.SH)涨6.6% 抗艾创新药ACC008上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/05/20131432786718.shtml",
    "datetime": "2021-05-20 13:14:40",
    "code": "688488"
  },
  {
    "title": "艾迪药业：ACC008上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/05/20114632786438.shtml",
    "datetime": "2021-05-20 11:46:42",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：ACC008上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2021/05/19170032782192.shtml",
    "datetime": "2021-05-19 17:00:11",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：今年累计获400.28万元政府补助",
    "href": "http://stock.jrj.com.cn/2021/05/17163732769499.shtml",
    "datetime": "2021-05-17 16:37:45",
    "code": "688488"
  },
  {
    "title": "艾迪药业：截至目前ACC007项目仍处于CDE正常审评程序中",
    "href": "http://stock.jrj.com.cn/2021/05/10163832730077.shtml",
    "datetime": "2021-05-10 16:38:50",
    "code": "688488"
  },
  {
    "title": "艾迪药业：第一期员工持股计划完成股票购买",
    "href": "http://stock.jrj.com.cn/2021/05/01065332943650.shtml",
    "datetime": "2021-05-01 06:53:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业：第一期员工持股计划完成股票购买",
    "href": "http://stock.jrj.com.cn/2021/05/01065132500789.shtml",
    "datetime": "2021-05-01 06:51:51",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：第一期员工持股计划完成股票购买",
    "href": "http://stock.jrj.com.cn/2021/04/30210732489394.shtml",
    "datetime": "2021-04-30 21:07:16",
    "code": "688488"
  },
  {
    "title": "艾迪药业一季报表现亮眼：营收大幅增长 净利润同比增近3倍",
    "href": "http://stock.jrj.com.cn/2021/04/29130132479517.shtml",
    "datetime": "2021-04-29 13:01:34",
    "code": "688488"
  },
  {
    "title": "艾迪药业年报：人源蛋白业务优势不断夯实 创新药物研发取得多项进展",
    "href": "http://stock.jrj.com.cn/2021/04/16173232387569.shtml",
    "datetime": "2021-04-16 17:32:09",
    "code": "688488"
  },
  {
    "title": "艾迪药业去年利润同比增长18% 主要产品收入87%来自一大客户",
    "href": "http://stock.jrj.com.cn/2021/04/15121532378563.shtml",
    "datetime": "2021-04-15 12:15:16",
    "code": "688488"
  },
  {
    "title": "降收反增利！艾迪药业去年营收下滑近两成",
    "href": "http://stock.jrj.com.cn/2021/04/15104832378012.shtml",
    "datetime": "2021-04-15 10:48:54",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：2020年度净利升18.2%至3977.18万元 拟10派0.48元",
    "href": "http://stock.jrj.com.cn/2021/04/14191432373148.shtml",
    "datetime": "2021-04-14 19:14:45",
    "code": "688488"
  },
  {
    "title": "艾迪药业2020年度净利3907.34万增长16.12% 人源蛋白业务中尤瑞克林粗品销售增长",
    "href": "http://stock.jrj.com.cn/2021/02/25204132027746.shtml",
    "datetime": "2021-02-25 20:41:12",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)业绩快报：2020年度净利润升16.12%至3907.34万元",
    "href": "http://stock.jrj.com.cn/2021/02/25183732027054.shtml",
    "datetime": "2021-02-25 18:37:02",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)拟推第一期员工持股计划",
    "href": "http://stock.jrj.com.cn/2021/02/08190331871660.shtml",
    "datetime": "2021-02-08 19:03:24",
    "code": "688488"
  },
  {
    "title": "龙泽制药启动上市辅导：曾获艾迪药业5000万元战略投资",
    "href": "http://stock.jrj.com.cn/2021/01/25185331767727.shtml",
    "datetime": "2021-01-25 18:53:53",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：265.1594万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2021/01/12161331676662.shtml",
    "datetime": "2021-01-12 16:13:28",
    "code": "688488"
  },
  {
    "title": "为完善抗病毒领域布局，艾迪药业拟向龙泽制药投资5000万元",
    "href": "http://stock.jrj.com.cn/2021/01/08101031653222.shtml",
    "datetime": "2021-01-08 10:10:26",
    "code": "688488"
  },
  {
    "title": "艾迪药业拟以5000万元对龙泽制药投资",
    "href": "http://stock.jrj.com.cn/2021/01/07215431650239.shtml",
    "datetime": "2021-01-07 21:54:17",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)拟对龙泽制药投资5000万元 将获得其增资后4.76%股权",
    "href": "http://stock.jrj.com.cn/2021/01/07182231649224.shtml",
    "datetime": "2021-01-07 18:22:18",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)拟向参股公司香港优瑞增资",
    "href": "http://stock.jrj.com.cn/2021/01/07182131649217.shtml",
    "datetime": "2021-01-07 18:21:14",
    "code": "688488"
  },
  {
    "title": "艾迪药业签署《年度采购框架合同》 每年度交易金额不低于2亿元",
    "href": "http://stock.jrj.com.cn/2020/12/23210831555932.shtml",
    "datetime": "2020-12-23 21:08:07",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)与天普生化签署年度采购框架合同",
    "href": "http://stock.jrj.com.cn/2020/12/23155231554028.shtml",
    "datetime": "2020-12-23 15:52:44",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)与天普生化签署采购合同",
    "href": "http://stock.jrj.com.cn/2020/12/23154631553983.shtml",
    "datetime": "2020-12-23 15:46:12",
    "code": "688488"
  },
  {
    "title": "艾迪药业：公司ACC007片作为国产创新药物 上市后有望保持优势",
    "href": "http://stock.jrj.com.cn/2020/12/04170931408890.shtml",
    "datetime": "2020-12-04 17:09:31",
    "code": "688488"
  },
  {
    "title": "艾迪药业：与韩国康佳诺签署合作备忘录 拟设合资公司共同开拓海外市场",
    "href": "http://stock.jrj.com.cn/2020/11/24144231337856.shtml",
    "datetime": "2020-11-24 14:42:29",
    "code": "688488"
  },
  {
    "title": "艾迪药业：公司积极以经销美国雅培公司HIV诊断设备及试剂业务产品为抓手 构建营销网络",
    "href": "http://stock.jrj.com.cn/2020/11/23084931332350.shtml",
    "datetime": "2020-11-23 08:49:28",
    "code": "688488"
  },
  {
    "title": "艾迪药业：公司产品与前沿生物产品在适应症领域、给药途径以及患者群体方面存在明显不同",
    "href": "http://stock.jrj.com.cn/2020/11/23084831332342.shtml",
    "datetime": "2020-11-23 08:48:29",
    "code": "688488"
  },
  {
    "title": "艾迪药业：公司目前正在开展ACC008片的生物等效性试验",
    "href": "http://stock.jrj.com.cn/2020/11/23084731332341.shtml",
    "datetime": "2020-11-23 08:47:25",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：与韩国Kainos签订合作备忘录",
    "href": "http://stock.jrj.com.cn/2020/11/22150531331276.shtml",
    "datetime": "2020-11-22 15:05:58",
    "code": "688488"
  },
  {
    "title": "艾迪药业：与韩国Kainos签署合作备忘录",
    "href": "http://stock.jrj.com.cn/2020/11/22142531331174.shtml",
    "datetime": "2020-11-22 14:25:31",
    "code": "688488"
  },
  {
    "title": "艾迪药业(688488.SH)：顺利完成ACC007片注册现场核查",
    "href": "http://stock.jrj.com.cn/2020/11/12171031268440.shtml",
    "datetime": "2020-11-12 17:10:12",
    "code": "688488"
  },
  {
    "title": "艾迪药业：2020年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/10/28001031145362.shtml",
    "datetime": "2020-10-28 00:10:04",
    "code": "688488"
  },
  {
    "title": "艾迪药业前三季度净利2959.06万增长147.7% 销售队伍人员精简",
    "href": "http://stock.jrj.com.cn/2020/10/27192531143770.shtml",
    "datetime": "2020-10-27 19:25:40",
    "code": "688488"
  },
  {
    "title": "艾迪药业：2020年第四次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/09/30001030862239.shtml",
    "datetime": "2020-09-30 00:10:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业：召开2020年第四次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2020/09/11135030729252.shtml",
    "datetime": "2020-09-11 13:50:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业：目前暂无计划将抗艾滋病药物用于新冠病毒治疗试验",
    "href": "http://stock.jrj.com.cn/2020/09/08100830701829.shtml",
    "datetime": "2020-09-08 10:08:16",
    "code": "688488"
  },
  {
    "title": "艾迪药业今日上市 加快布局创研新药",
    "href": "http://stock.jrj.com.cn/2020/07/20130630292270.shtml",
    "datetime": "2020-07-20 13:06:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业中签号出炉 中签号码共32429个",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/09075430187313.shtml",
    "datetime": "2020-07-09 07:54:15",
    "code": "688488"
  },
  {
    "title": "【兑奖啦】科创板艾迪药业网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/08192030181798.shtml",
    "datetime": "2020-07-08 19:20:29",
    "code": "688488"
  },
  {
    "title": "【兑奖啦】科创板中芯国际、慧辰资讯、艾迪药业网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/08191730181779.shtml",
    "datetime": "2020-07-08 19:17:49",
    "code": "688488"
  },
  {
    "title": "艾迪药业科创板IPO融资7.46亿元 转型跨越性较大 | 产业新股",
    "href": "http://stock.jrj.com.cn/2020/07/07200230169787.shtml",
    "datetime": "2020-07-07 20:02:25",
    "code": "688488"
  },
  {
    "title": "艾迪药业：网上发行最终中签率为0.04014192％",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/07191930169498.shtml",
    "datetime": "2020-07-07 19:19:17",
    "code": "688488"
  },
  {
    "title": "今日新股申购：中芯国际、艾迪药业、慧辰资讯",
    "href": "http://stock.jrj.com.cn/2020/07/07090930162602.shtml",
    "datetime": "2020-07-07 09:09:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业IPO：实控人前控股公司掌握着“命脉”研发投入资本化率高疑似虚增利润",
    "href": "http://stock.jrj.com.cn/2020/07/07082630163160.shtml",
    "datetime": "2020-07-07 08:26:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业今日申购 顶格申购需配市值10.5万元",
    "href": "http://stock.jrj.com.cn/ipo/2020/07/07075330162554.shtml",
    "datetime": "2020-07-07 07:53:59",
    "code": "688488"
  },
  {
    "title": "科创板新股中芯国际、慧辰资讯、艾迪药业7月7日申购宝典",
    "href": "http://stock.jrj.com.cn/kcb/2020/07/06153830153613.shtml",
    "datetime": "2020-07-06 15:38:30",
    "code": "688488"
  },
  {
    "title": "艾迪药业披露招股意向书 拟发行6000万股新股",
    "href": "http://stock.jrj.com.cn/2020/07/01103730108762.shtml",
    "datetime": "2020-07-01 10:37:00",
    "code": "688488"
  },
  {
    "title": "科创板助力 艾迪药业大规模创研新药将驶入快车道",
    "href": "http://stock.jrj.com.cn/2020/07/01093930107964.shtml",
    "datetime": "2020-07-01 09:39:30",
    "code": "688488"
  },
  {
    "title": "证监会同意艾迪药业等2家科创板企业IPO注册",
    "href": "http://stock.jrj.com.cn/2020/06/18220729959865.shtml",
    "datetime": "2020-06-18 22:07:00",
    "code": "688488"
  },
  {
    "title": "上交所：艾迪药业科创板首发过会",
    "href": "http://stock.jrj.com.cn/ipo/2020/06/01171029816274.shtml",
    "datetime": "2020-06-01 17:10:18",
    "code": "688488"
  },
  {
    "title": "艾迪药业闯科创板：即将二次上会，主营行业改为“其他制造业",
    "href": "http://stock.jrj.com.cn/2020/05/26160229768725.shtml",
    "datetime": "2020-05-26 16:02:21",
    "code": "688488"
  },
  {
    "title": "艾迪药业、赛科希德、高测股份6月1日科创板上会",
    "href": "http://stock.jrj.com.cn/2020/05/22090129737633.shtml",
    "datetime": "2020-05-22 09:01:00",
    "code": "688488"
  },
  {
    "title": "艾迪药业重新“交卷” 科创板IPO即将二次上会",
    "href": "http://stock.jrj.com.cn/2020/05/22085929737611.shtml",
    "datetime": "2020-05-22 08:59:26",
    "code": "688488"
  },
  {
    "title": "艾迪药业成今年科创板暂缓审议第1家 人源蛋白不是药",
    "href": "http://stock.jrj.com.cn/2020/04/29103229416886.shtml",
    "datetime": "2020-04-29 10:32:00",
    "code": "688488"
  },
  {
    "title": "科创板上四过三维持高通过率 艾迪药业因需补充披露事项遭暂缓",
    "href": "http://stock.jrj.com.cn/2020/04/29081729608439.shtml",
    "datetime": "2020-04-29 08:17:00",
    "code": "688488"
  },
  {
    "title": "四过三！艾迪药业科创板IPO按下“暂停键”",
    "href": "http://stock.jrj.com.cn/kcb/2020/04/29072829413741.shtml",
    "datetime": "2020-04-29 07:28:50",
    "code": "688488"
  },
  {
    "title": "艾迪药业、皖仪科技4月28日科创板上会",
    "href": "http://stock.jrj.com.cn/2020/04/20091629326946.shtml",
    "datetime": "2020-04-20 09:16:00",
    "code": "688488"
  },
  {
    "title": "科创板上市委：艾迪药业、皖仪科技首发4月28日上会",
    "href": "http://stock.jrj.com.cn/2020/04/19192729320947.shtml",
    "datetime": "2020-04-19 19:27:00",
    "code": "688488"
  },
  {
    "title": "闯关科创板遭质疑不断 艾迪药业能否顺利上市仍是谜",
    "href": "http://stock.jrj.com.cn/kcb/2020/01/13072728664976.shtml",
    "datetime": "2020-01-13 07:27:48",
    "code": "688488"
  },
  {
    "title": "艾迪药业“左右逢源”：与原料药企比财务，与创新药企比未来",
    "href": "http://stock.jrj.com.cn/2019/12/19175228559241.shtml",
    "datetime": "2019-12-19 17:52:41",
    "code": "688488"
  },
  {
    "title": "艾迪药业IPO玄机：大客户系实控人创立",
    "href": "http://stock.jrj.com.cn/kcb/2019/11/27013128454836.shtml",
    "datetime": "2019-11-27 01:31:25",
    "code": "688488"
  },
  {
    "title": "艾迪药业拟科创板上市：单一客户贡献六成营收 在研抗艾抗瘤药",
    "href": "http://stock.jrj.com.cn/kcb/2019/10/17070528259257.shtml",
    "datetime": "2019-10-17 07:05:42",
    "code": "688488"
  },
  {
    "title": "上交所受理艾迪药业科创板上市申请 半数研发费用资本化",
    "href": "http://stock.jrj.com.cn/2019/10/10175128227722.shtml",
    "datetime": "2019-10-10 17:51:59",
    "code": "688488"
  },
  {
    "title": "艾迪药业科创板上市申请获受理",
    "href": "http://stock.jrj.com.cn/2019/10/10171028227439.shtml",
    "datetime": "2019-10-10 17:10:00",
    "code": "688488"
  }
]